Table 1.

Clinical trials of targeted ICP in Pca.

Target	Drug	Phase	Status	Clinical Trials identifier	Ref.
CTLA-4	Ipilimumab	II	Completed	NCT00112580	120
	Ipilimumab ± GVAX	I	Completed	NCT00836407	121
	Ipilimumab + GVAX	II	Recruiting	NCT01896869	175
	Ipilimumab + gemcitabine	Ib	Completed	NCT01473940	122
	Ipilimumab + nivolumab with radiation	II	Recruiting	NCT03104439	123
	Tremelimumab (CP-675,206) + gemcitabine	Ib	Completed	NCT00556023	128
	Tremelimumab + durvalumab	II	Completed	NCT02558894	127
PD-1	Pembrolizumab + REOLYSIN + chemotherapy	II	Recruiting	NCT02620423	137
	Pembrolizumab + ACP-196	II	Active but not recruiting	NCT02362048	136
	Pembrolizumab (MK3475)	I/II	Recruiting	NCT02305186	135
	Pembrolizumab + PLX3397	I	Recruiting	NCT02452424	134
	Pembrolizumab + oncolytic virus pelareorep	Ib	Recruiting	NCT02620423	138
	Pembrolizumab + PEGPH20	II	Recruiting	NCT03634332	139
	Pembrolizumab + NOX-A12	II	Completed	NCT03168139	176
	Nivolumab + GVAX + cyclophosphamide	I/II	Active but not recruiting	NCT02451982	144
	Nivolumab + Nab-paclitaxel + gemcitabine	I	Recruiting	NCT02309177	143
	Nivolumab + GVAX + CRS-207	II	Recruiting	NCT02243371	142
	Nivolumab + cabiralizumab + chemotherapy	II	Active but not recruiting	NCT03336216	145
	Nivolumab + SD-101	I	Recruiting	NCT04050085	146
PD-L1	BMS-936559	I	Completed	NCT00729664	9,166
	Durvalumab + ibrutinib mesylate	Ib/II	Recruiting	NCT02403271	150
	Durvalumab + galunisertib	1 b	Completed	NCT02734160	151
	Durvalumab + stereotactic radiotherapy	I/II	Recruiting	NCT03245541	152
	Durvalumab + pexidartinib	I	Completed	NCT02777710	153
PD-L1, CTLA-4	Tremelimumab + MEDI4736	I	Recruiting	NCT02311361	149
	Durvalumab + tremelimumab	II	Recruiting	NCT02558894	129